Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - ciltacabtagene autoleucel, quantity: 500000 cells/kg - injection, intravenous infusion - excipient ingredients: dimethyl sulfoxide - cellular therapies - carvykti is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-cd38 antibody.